Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rudin

Showing results (291-300 of 524) with videos related to

Pageof 53
Sort By:
The Oncologist|August 9, 2023
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399Ryan D Gentzler, Liza C Villaruz, John C Rhee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 13, 2024
Biomarkers associated with pulmonary exacerbations in a randomized trial of nintedanib for radiation pneumonitisZachary R Moore, Xiaojing Huang, Stephanie Lobaugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.
Oncogene|September 2, 2018
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancerZachary A Yochum, Jessica Cades, Hailun Wang, et al.
Nature|June 25, 2016
A combinatorial strategy for treating KRAS-mutant lung cancerEusebio Manchado, Susann Weissmueller, John P Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2014
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancerLuping Lin, Saurabh Asthana, Elton Chan, et al.
Journal of Hematology & Oncology|July 31, 2024
SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicingEsther Redin, Harsha Sridhar, Yingqian A Zhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2025
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 TrialCharles M Rudin, Melissa L Johnson, Luis Paz-Ares, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Delta-like Ligand 3-Directed <sup>225</sup>Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer ModelsTran T Hoang, David Bauer, Aidan Ingham, et al.
Cancer|May 11, 2016
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)Chandra P Belani, Suzanne E Dahlberg, Charles M Rudin, et al.
Pageof 53

Showing results (291-300 of 524) with videos related to

Sort By:
Pageof 53
The Oncologist|August 9, 2023
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399Ryan D Gentzler, Liza C Villaruz, John C Rhee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 13, 2024
Biomarkers associated with pulmonary exacerbations in a randomized trial of nintedanib for radiation pneumonitisZachary R Moore, Xiaojing Huang, Stephanie Lobaugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.
Oncogene|September 2, 2018
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancerZachary A Yochum, Jessica Cades, Hailun Wang, et al.
Nature|June 25, 2016
A combinatorial strategy for treating KRAS-mutant lung cancerEusebio Manchado, Susann Weissmueller, John P Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2014
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancerLuping Lin, Saurabh Asthana, Elton Chan, et al.
Journal of Hematology & Oncology|July 31, 2024
SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicingEsther Redin, Harsha Sridhar, Yingqian A Zhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2025
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 TrialCharles M Rudin, Melissa L Johnson, Luis Paz-Ares, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Delta-like Ligand 3-Directed <sup>225</sup>Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer ModelsTran T Hoang, David Bauer, Aidan Ingham, et al.
Cancer|May 11, 2016
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)Chandra P Belani, Suzanne E Dahlberg, Charles M Rudin, et al.
Pageof 53